Cullen Frost Bankers Inc. trimmed its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 0.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 340,629 shares of the company’s stock after selling 3,212 shares during the period. Cullen Frost Bankers Inc. owned approximately 0.07% of Zoetis worth $21,719,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in ZTS. AQR Capital Management LLC lifted its holdings in shares of Zoetis by 13.6% during the first quarter. AQR Capital Management LLC now owns 105,747 shares of the company’s stock valued at $5,644,000 after purchasing an additional 12,644 shares during the last quarter. Nomura Asset Management Co. Ltd. raised its holdings in Zoetis by 3.4% in the 1st quarter. Nomura Asset Management Co. Ltd. now owns 55,320 shares of the company’s stock worth $2,952,000 after acquiring an additional 1,800 shares during the last quarter. Bath Savings Trust Co purchased a new position in Zoetis in the 2nd quarter worth approximately $279,000. McQueen Ball & Associates Inc. bought a new stake in Zoetis in the 2nd quarter worth approximately $204,000. Finally, Copper Rock Capital Partners LLC grew its position in Zoetis by 77.0% in the 2nd quarter. Copper Rock Capital Partners LLC now owns 6,342 shares of the company’s stock worth $339,000 after purchasing an additional 2,759 shares during the period. Hedge funds and other institutional investors own 92.90% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Zoetis Inc. (ZTS) Shares Sold by Cullen Frost Bankers Inc.” was published by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/11/07/zoetis-inc-zts-shares-sold-by-cullen-frost-bankers-inc.html.

Shares of Zoetis Inc. (NYSE ZTS) traded down $0.79 during midday trading on Tuesday, hitting $68.92. 973,663 shares of the stock traded hands, compared to its average volume of 2,410,000. The stock has a market cap of $33,580.00, a PE ratio of 31.51, a price-to-earnings-growth ratio of 2.02 and a beta of 1.02. Zoetis Inc. has a 52-week low of $48.24 and a 52-week high of $70.48. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.80 and a quick ratio of 1.95.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, November 2nd. The company reported $0.65 EPS for the quarter, beating the consensus estimate of $0.63 by $0.02. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.32 billion. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The firm’s revenue was up 8.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.52 EPS. equities analysts forecast that Zoetis Inc. will post 2.35 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Thursday, November 9th will be issued a dividend of $0.105 per share. The ex-dividend date of this dividend is Wednesday, November 8th. This represents a $0.42 annualized dividend and a yield of 0.61%. Zoetis’s payout ratio is 22.11%.

A number of equities research analysts have recently issued reports on ZTS shares. BMO Capital Markets set a $65.00 price objective on shares of Zoetis and gave the company a “hold” rating in a research report on Wednesday, October 25th. BidaskClub raised shares of Zoetis from a “buy” rating to a “strong-buy” rating in a report on Tuesday, September 12th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $75.00 target price on shares of Zoetis in a report on Tuesday, October 24th. Deutsche Bank AG reaffirmed a “buy” rating and issued a $65.00 target price (up previously from $62.00) on shares of Zoetis in a report on Monday, July 17th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $65.00 target price on shares of Zoetis in a report on Friday, September 1st. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and eleven have assigned a buy rating to the company. Zoetis presently has an average rating of “Buy” and a consensus target price of $67.06.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.